Narendiran Rajasekaran to Humans
This is a "connection" page, showing publications Narendiran Rajasekaran has written about Humans.
Connection Strength
0.108
-
Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, Widmann K, Kapoor VN, Vexler V, Keegan P, Yao S, LaVallee T, Khare SD. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. 2024 Feb 24; 73(3):60.
Score: 0.045
-
Cluff E, Magdaleno CC, Fernandez E, House T, Swaminathan S, Varadaraj A, Rajasekaran N. Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells. Cancer Immunol Immunother. 2022 Aug; 71(8):1989-2005.
Score: 0.038
-
Magdaleno C, House T, Pawar JS, Carvalho S, Rajasekaran N, Varadaraj A. Fibronectin assembly regulates lumen formation in breast acini. J Cell Biochem. 2021 05; 122(5):524-537.
Score: 0.009
-
Magdaleno C, Dixon L, Rajasekaran N, Varadaraj A. HIFa independent mechanisms in renal carcinoma cells modulate divergent outcomes in fibronectin assembly mediated by hypoxia and CoCl2. Sci Rep. 2020 10 29; 10(1):18560.
Score: 0.009
-
Hebb JPO, Mosley AR, Vences-Catal?n F, Rajasekaran N, Ros?n A, Ellmark P, Felsher DW. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. Cancer Immunol Immunother. 2018 01; 67(1):47-60.
Score: 0.007